North American Respiratory Drug Market Size, Share & Trends Analysis Report by Route of Administration (Oral, Injectable, and Inhalable), by Application (Asthma and Chronic Obstructive Pulmonary Disease (COPD)), by End-User (Homecare and Hospitals and Clinics) and Forecast 2019-2025.
North American respiratory drug market was $18.0 billion in 2018 and is anticipated to grow at a substantial rate of 7.6% during the forecast period. The major factors that are contributing significantly to the market growth include rising air pollution, growing geriatric population, and high healthcare expenditure. The US and Canada are the major economies of North America. The rising prevalence of chronic respiratory diseases, increasing geriatric population, and technological advancement are the major factors augmenting the growth of the respiratory drug market in North America. The US is the major market due to greater healthcare expenditure and a higher prevalence rate of respiratory diseases.
The North American respiratory drug market is segmented on the basis of route of administration, application, and end-user. Based on the route of administration, the market is classified into oral, injectable, and inhalable. Moreover, on the basis of application, the market has been classified into asthma and COPD diseases. The asthma disease application segment dominated the regional market in 2018 and is further estimated to follow the same trend over the forecast period. This is mainly due to the high prevalence of asthma in the economies of the region such as the US and Canada. According to the Centers for Disease Control and Prevention (CDC) 2017, there are around 26 million asthmatics in the US, among which, nearly 18.9 million are adults and 7.1 million are children. In addition, based on the end-user, homecare and hospitals and clinics have been analyzed.
Furthermore, the market is characterized by the presence of several manufacturers that are developing and providing respiratory drug to cater to a wide range of customers within and outside the region. The major players of the North American respiratory drug market include AstraZeneca PLC, GlaxoSmithKline PLC, Novartis AG, and Teva Pharmaceuticals Industries Ltd. These players adopt various strategies to capitalize on market growth opportunities. Mergers and acquisitions, product launch, geographical expansion, partnerships, and collaborations are the majorly adopted strategies by the market players.
Research Methodology
The market study of the North American respiratory drug market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors.
Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. the analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of the reports.
Secondary Sources Include:
Market Segmentation:
1. North American Respiratory Drug Market Research and Analysis by Route of Administration
2. North American Respiratory Drug Market Research and Analysis by Application
3. North American Respiratory Drug Market Research and Analysis by End-User
The Report Covers:
North American respiratory drug market was $18.0 billion in 2018 and is anticipated to grow at a substantial rate of 7.6% during the forecast period. The major factors that are contributing significantly to the market growth include rising air pollution, growing geriatric population, and high healthcare expenditure. The US and Canada are the major economies of North America. The rising prevalence of chronic respiratory diseases, increasing geriatric population, and technological advancement are the major factors augmenting the growth of the respiratory drug market in North America. The US is the major market due to greater healthcare expenditure and a higher prevalence rate of respiratory diseases.
The North American respiratory drug market is segmented on the basis of route of administration, application, and end-user. Based on the route of administration, the market is classified into oral, injectable, and inhalable. Moreover, on the basis of application, the market has been classified into asthma and COPD diseases. The asthma disease application segment dominated the regional market in 2018 and is further estimated to follow the same trend over the forecast period. This is mainly due to the high prevalence of asthma in the economies of the region such as the US and Canada. According to the Centers for Disease Control and Prevention (CDC) 2017, there are around 26 million asthmatics in the US, among which, nearly 18.9 million are adults and 7.1 million are children. In addition, based on the end-user, homecare and hospitals and clinics have been analyzed.
Furthermore, the market is characterized by the presence of several manufacturers that are developing and providing respiratory drug to cater to a wide range of customers within and outside the region. The major players of the North American respiratory drug market include AstraZeneca PLC, GlaxoSmithKline PLC, Novartis AG, and Teva Pharmaceuticals Industries Ltd. These players adopt various strategies to capitalize on market growth opportunities. Mergers and acquisitions, product launch, geographical expansion, partnerships, and collaborations are the majorly adopted strategies by the market players.
Research Methodology
The market study of the North American respiratory drug market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors.
Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. the analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of the reports.
Secondary Sources Include:
- Financial reports of companies involved in the market
- Whitepapers, research-papers, and news blogs
- Company websites and their product catalog
Market Segmentation:
1. North American Respiratory Drug Market Research and Analysis by Route of Administration
2. North American Respiratory Drug Market Research and Analysis by Application
3. North American Respiratory Drug Market Research and Analysis by End-User
The Report Covers:
- Comprehensive research methodology of the North American respiratory drug market.
- This report also includes a detailed and extensive market overview with key analyst insights.
- An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the North American respiratory drug market.
- Insights about market determinants which are stimulating the North American respiratory drug market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
Table of Contents
1. Report Summary
2. Market Overview and Insights
3. Competitive Landscape
4. Market Determinants
5. Market Segmentation
6. Regional Analysis
7. Company Profiles
Companies Mentioned
A selection of companies mentioned in this report includes:
- Air Liquide S.A.
- Aradigm Corp.
- AstraZeneca PLC
- Baxter International Inc.
- Boehringer Ingelheim International GmbH
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline PLC
- Merck & Co.
- Novartis AG
- Omron Healthcare Inc.
- Pfizer Inc.
- Pulmatrix Inc.
- ResMed Corp.
- Savara, Inc.
- Sunovion Pharmaceuticals
- Takeda Pharmaceutical Company Ltd.
- Teva Pharmaceuticals Industries Ltd.